Abstract:Adenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson's disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H3 receptor (H3R) antagonists in combination with the "caffeine-like effects" of A1R/A2AR antagonists, we designed A1R/A2AR/H3R MTLs, where a piperidino-/pyrrolidino(propyloxy)phenyl H3R pharmacophore was introduced with overlap into an adenosine antagonist arylindenopyrimidine core. These MTLs showed distinct receptor binding profiles with overall nanomolar H3R affinities (Ki < 55 nM). Compound 4 (ST-2001, Ki (A1R) = 11.5 nM, Ki (A2AR) = 7.25 nM) and 12 (ST-1992, Ki (A1R) = 11.2 nM, Ki (A2AR) = 4.01 nM) were evaluated in vivo. l-DOPA-induced dyskinesia was improved after administration of compound 4 (1 mg kg–1, i.p. rats). Compound 12 (2 mg kg–1, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00914?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00914</a>.Spectroscopic and analytical data; general LC–MS analytics; general synthesis, fluorescence characterization of compound 12 (ST-1992); drug-likeness of synthetized MTLs 4 (ST-2001) and 12 (ST-1992); cell viability of human neuroblastoma cells treated with MTLs 2, 4 (ST-2001) , and 6; in vitro radioligand binding experiments for compounds 4 (ST-2001) and 12 (ST-1992); in vivo studies of compound 4 (ST-2001); additional in vivo evaluation of compound 12 (ST-1992); and experimental part with references (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_002.csv">CSV</a>)Modeling structure of A2AR with preladenant (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_003.pdb">PDB</a>)Modeling structure of A2AR with ST-1992 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_004.pdb">PDB</a>)This article has not yet been cited by other publications.

Discovery of Indolylpiperazinylpyrimidines with Dual-Target Profiles at Adenosine A2A and Dopamine D2 Receptors for Parkinson's Disease Treatment.

Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines As A(2a) Adenosine Receptor Antagonists for the Treatment of Parkinson'S Disease

Optimization of 6-Heterocyclic-2-(1h-pyrazol-1-yl)-n-(pyridin-2-yl)pyrimidin-4-amine As Potent Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease.

Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease.

Discovery of Novel Benzimidazole Derivatives as Selective and Reversible Monoamine Oxidase B Inhibitors for Parkinson's Disease Treatment

Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease Through Comparative Structure-Based Virtual Screening

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Novel 1-(Prop-2-yn-1-ylamino)-2,3-dihydro-1h-indene-4-thiol Derivatives As Potent Selective Human Monoamine Oxidase B Inhibitors: Design, SAR Development, and Biological Evaluation.

(6Ar)-11-amino-n-propyl-noraporphine, A New Dopamine D-2 and Serotonin 5-Ht1a Dual Agonist, Elicits Potent Antiparkinsonian Action and Attenuates Levodopa-Induced Dyskinesia in A 6-Ohda-lesioned Rat Model of Parkinson'S Disease

Discovery and structure - activity relationships of 2,4,5-trimethoxyphenyl pyrimidine derivatives as selective D5 receptor partial agonists

Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT1A Receptors As New Antipsychotical or Anti-Parkinsonian Agents.

Design, Synthesis, Immunocytochemistry Evaluation, and Molecular Docking Investigation of Several 4-Aminopyridine Derivatives As Potential Neuroprotective Agents for Treating Parkinson'S Disease

Design and Synthesis of Five‐membered Heterocyclic Derivatives of Istradefylline with Comparable Pharmacological Activity

Adenosine A 2A R/A 1 R Antagonists Enabling Additional H 3 R Antagonism for the Treatment of Parkinson’s Disease

Identification of Novel, Water-Soluble, 2-Amino-n-pyrimidin-4-yl Acetamides As A2A Receptor Antagonists with in Vivo Efficacy

Development of Adenosine A 2A Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge.

Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors

Brain-Specific Delivery of Dopamine Mediated by N,N-Dimethyl Amino Group for the Treatment of Parkinson’s Disease

Identification and Optimization of Nitrophenolic Analogues As Dopamine Metabolic Enzyme Inhibitors for the Treatment of Parkinson’s Disease

Computer-Aided Design and Biological Evaluation of Diazaspirocyclic D4R Antagonists

Optimization of N -Phenylpropenoyl- l -amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease